We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cutaneous B-cell pseudolymphoma treated with rituximab and methotrexate.
- Authors
Besch-Stokes, Jake G.; Patel, Meera H.; Brumfiel, Caitlin M.; Costello, Collin M.; Rule, William; Rosenthal, Allison; Pittelkow, Mark R.; DiCaudo, David J.; Mangold, Aaron R.
- Abstract
Cutaneous B-cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL. Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions.
- Subjects
B cell tumors; RITUXIMAB; METHOTREXATE; HYPERPLASIA treatment; TREATMENT effectiveness; SKIN disease treatment
- Publication
Dermatology Online Journal, 2021, Vol 27, Issue 9, p1
- ISSN
1087-2108
- Publication type
Article
- DOI
10.5070/D327955138